FDA label cf313cc0-44c0-4f55-a021-8fab00af41ca

5 WARNINGS AND PRECAUTIONS Severe, potentially life-threatening and fatal skin reactions have been reported. This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis. Immediately discontinue treatment with ISENTRESS and other suspect agents if severe hypersensitivity, severe rash, or rash with systemic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely ( 5.1 ). Monitor for Immune Reconstitution Syndrome ( 5.2 ). Inform patients with phenylketonuria that the 100 mg and 25 mg chewable tablets contain phenylalanine ( 5.3 ). 5.1 Severe Skin and Hypersensitivity Reactions Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure. Discontinue ISENTRESS and other suspect agents immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Delay in stopping ISENTRESS treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction. 5.2 Immune Reconstitution Syndrome Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including ISENTRESS. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia, tuberculosis), which may necessitate further evaluation and treatment. Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment. 5.3 Phenylketonurics ISENTRESS Chewable Tablets contain phenylalanine, a component of aspartame. Each 25 mg ISENTRESS Chewable Tablet contains approximately 0.05 mg phenylalanine. Each 100 mg ISENTRESS Chewable Tablet contains approximately 0.10 mg phenylalanine. Phenylalanine can be harmful to patients with phenylketonuria.

6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions of moderate to severe intensity (≥2%) are insomnia, headache, nausea and fatigue ( 6.1 and 6.2 ). Creatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and rhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions ( 6.3 ). To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience: Treatment-Naïve Adults The following safety assessment of ISENTRESS in treatment-naïve subjects is based on the randomized double-blind active controlled study of treatment-naïve subjects, STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed dose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600 mg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-blind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily + emtricitabine (+) tenofovir was 748 patient-years and 715 patient-years for subjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenofovir. In Protocol 021, the rate of discontinuation of therapy due to adverse events was 5% in subjects receiving ISENTRESS + emtricitabine (+) tenofovir and 9% in subjects receiving efavirenz + emtricitabine (+) tenofovir. The clinical adverse drug reactions (ADRs) listed below were considered by investigators to be causally related to ISENTRESS + emtricitabine (+) tenofovir or efavirenz + emtricitabine (+) tenofovir. Clinical ADRs of moderate to severe intensity occurring in ≥2% of treatment-naïve subjects treated with ISENTRESS are presented in Table 2 . Table 2: Adverse Drug Reactions Includes adverse experiences considered by investigators to be at least possibly, probably, or definitely related to the drug. of Moderate to Severe Intensity Intensities are defined as follows: Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating with inability to work or do usual activity). Occurring in ≥2% of Treatment-Naïve Adult Subjects Receiving ISENTRESS (156 Week Analysis) System Organ Class, Preferred Term Randomized Study Protocol 021 ISENTRESS 400 mg Twice Daily + Emtricitabine (+) Tenofovir (n = 281) n = total number of subjects per treatment group Efavirenz 600 mg At Bedtime + Emtricitabine (+) Tenofovir (n = 282) Psychiatric Disorders Insomnia 4% 4% Nervous System Disorders Headache 4% 5% Gastrointestinal Disorders Nausea 3% 4% General Disorders and Administration Fatigue 2% 3% Laboratory Abnormalities The percentages of adult subjects treated with ISENTRESS 400 mg twice daily or efavirenz in Protocol 021 with selected Grades 2 to 4 laboratory abnormalities that represent a worsening Grade from baseline are presented in Table 3 . Table 3: Selected Grade 2 to 4 Laboratory Abnormalities Reported in Treatment-Naïve Subjects (156 Week Analysis) Randomized Study Protocol 021 Laboratory Parameter Preferred Term (Unit) Limit ISENTRESS 400 mg Twice Daily + Emtricitabine (+) Tenofovir (N = 281) Efavirenz 600 mg At Bedtime + Emtricitabine (+) Tenofovir (N = 282) ULN = Upper limit of normal range Hematology Absolute neutrophil count (10 3 /µL) Grade 2 0.75 - 0.999 3% 5% Grade 3 0.50 - 0.749 2% 1% Grade 4 <0.50 <1% <1% Hemoglobin (gm/dL) Grade 2 7.5 - 8.4 1% 1% Grade 3 6.5 - 7.4 <1% 1% Grade 4 <6.5 <1% 0% Platelet count (10 3 /µL) Grade 2 50 - 99.999 2% 0% Grade 3 25 - 49.999 <1% <1% Grade 4 <25 0% 0% Blood chemistry Fasting (non-random) serum glucose test (mg/dL) Grade 2 126 - 250 4% 5% Grade 3 251 - 500 1% 1% Grade 4 >500 0% 0% Total serum bilirubin Grade 2 1.6 - 2.5 × ULN 5% 0% Grade 3 2.6 - 5.0 × ULN 1% 0% Grade 4 >5.0 × ULN <1% 0% Serum aspartate aminotransferase Grade 2 2.6 - 5.0 × ULN 5% 7% Grade 3 5.1 - 10.0 × ULN 3% 3% Grade 4 >10.0 × ULN 1% <1% Serum alanine aminotransferase Grade 2 2.6 - 5.0 × ULN 10% 9% Grade 3 5.1 - 10.0 × ULN 1% 2% Grade 4 >10.0 × ULN 1% 1% Serum alkaline phosphatase Grade 2 2.6 - 5.0 × ULN 1% 3% Grade 3 5.1 - 10.0 × ULN 0% <1% Grade 4 >10.0 × ULN 0% <1% Lipids, Change from Baseline Changes from baseline in fasting lipids are shown in Table 4 . Table 4: Lipid Values, Mean Change from Baseline, Protocol 021 Laboratory Parameter Preferred Term ISENTRESS 400 mg Twice Daily + Emtricitabine (+) Tenofovir N = 281 Efavirenz 600 mg At Bedtime + Emtricitabine (+) Tenofovir N = 282 Change from Baseline at Week 144 Change from Baseline at Week 144 Baseline Mean (mg/dL) Week 144 Mean (mg/dL) Mean Change (mg/dL) Baseline Mean (mg/dL) Week 144 Mean (mg/dL) Mean Change (mg/dL) Notes: N = Number of subjects in the treatment group. The analysis is based on all available data. If subjects initiated or increased serum lipid-reducing agents, the last available lipid values prior to the change in therapy were used in the analysis. If the missing data was due to other reasons, subjects were censored thereafter for the analysis. At baseline, serum lipid-reducing agents were used in 5% of subjects in the group receiving ISENTRESS and 3% in the efavirenz group. Through Week 144, serum lipid-reducing agents were used in 9% of subjects in the group receiving ISENTRESS and 10% in the efavirenz group. LDL-Cholesterol Fasting (non-random) laboratory tests at Week 144. 97 105 7 92 115 22 HDL-Cholesterol 38 43 4 38 48 11 Total Cholesterol 160 172 13 156 195 39 Triglyceride 126 127 1 139 173 35 6.2 Clinical Trials Experience: Treatment-Experienced Adults The safety assessment of ISENTRESS in treatment-experienced subjects is based on the pooled safety data from the randomized, double-blind, placebo-controlled trials, BENCHMRK 1 and BENCHMRK 2 (Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult subjects. A total of 462 subjects received the recommended dose of ISENTRESS 400 mg twice daily in combination with optimized background therapy (OBT) compared to 237 subjects taking placebo in combination with OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving ISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to ISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of discontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5% in subjects receiving placebo. Clinical ADRs were considered by investigators to be causally related to ISENTRESS + OBT or placebo + OBT. Clinical ADRs of moderate to severe intensity occurring in ≥2% of subjects treated with ISENTRESS and occurring at a higher rate compared to placebo are presented in Table 5 . Table 5: Adverse Drug Reactions Includes adverse reactions at least possibly, probably, or definitely related to the drug. of Moderate to Severe Intensity Intensities are defined as follows: Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating with inability to work or do usual activity). Occurring in ≥2% of Treatment-Experienced Adult Subjects Receiving ISENTRESS and at a Higher Rate Compared to Placebo (96 Week Analysis) System Organ Class, Adverse Reactions Randomized Studies Protocol 018 and 019 ISENTRESS 400 mg Twice Daily + OBT (n = 462) n=total number of subjects per treatment group. Placebo + OBT (n = 237) Nervous System Disorders Headache 2% <1% Laboratory Abnormalities The percentages of adult subjects treated with ISENTRESS 400 mg twice daily or placebo in Protocols 018 and 019 with selected Grade 2 to 4 laboratory abnormalities representing a worsening Grade from baseline are presented in Table 6 . Table 6: Selected Grade 2 to 4 Laboratory Abnormalities Reported in Treatment-Experienced Subjects (96 Week Analysis) Randomized Studies Protocol 018 and 019 Laboratory Parameter Preferred Term (Unit) Limit ISENTRESS 400 mg Twice Daily + OBT (N = 462) Placebo + OBT (N = 237) ULN = Upper limit of normal range Hematology Absolute neutrophil count (10 3 /µL) Grade 2 0.75 - 0.999 4% 5% Grade 3 0.50 - 0.749 3% 3% Grade 4 <0.50 1% <1% Hemoglobin (gm/dL) Grade 2 7.5 - 8.4 1% 3% Grade 3 6.5 - 7.4 1% 1% Grade 4 <6.5 <1% 0% Platelet count (10 3 /µL) Grade 2 50 - 99.999 3% 5% Grade 3 25 - 49.999 1% <1% Grade 4 <25 1% <1% Blood chemistry Fasting (non-random) serum glucose test (mg/dL) Grade 2 126 - 250 10% 7% Grade 3 251 - 500 3% 1% Grade 4 >500 0% 0% Total serum bilirubin Grade 2 1.6 - 2.5 × ULN 6% 3% Grade 3 2.6 - 5.0 × ULN 3% 3% Grade 4 >5.0 × ULN 1% 0% Serum aspartate aminotransferase Grade 2 2.6 - 5.0 × ULN 9% 7% Grade 3 5.1 - 10.0 × ULN 4% 3% Grade 4 >10.0 × ULN 1% 1% Serum alanine aminotransferase Grade 2 2.6 - 5.0 × ULN 9% 9% Grade 3 5.1 - 10.0 × ULN 4% 2% Grade 4 >10.0 × ULN 1% 2% Serum alkaline phosphatase Grade 2 2.6 - 5.0 × ULN 2% <1% Grade 3 5.1 - 10.0 × ULN <1% 1% Grade 4 >10.0 × ULN 1% <1% Serum pancreatic amylase test Grade 2 1.6 - 2.0 × ULN 2% 1% Grade 3 2.1 - 5.0 × ULN 4% 3% Grade 4 >5.0 × ULN <1% <1% Serum lipase test Grade 2 1.6 - 3.0 × ULN 5% 4% Grade 3 3.1 - 5.0 × ULN 2% 1% Grade 4 >5.0 × ULN 0% 0% Serum creatine kinase Grade 2 6.0 - 9.9 × ULN 2% 2% Grade 3 10.0 - 19.9 × ULN 4% 3% Grade 4 ≥20.0 × ULN 3% 1% Less Common Adverse Reactions Observed in Treatment-Naïve and Treatment-Experienced Studies The following ADRs occurred in <2% of treatment-naïve or treatment-experienced subjects receiving ISENTRESS in a combination regimen. These events have been included because of their seriousness, increased frequency on ISENTRESS compared with efavirenz or placebo, or investigator's assessment of potential causal relationship. Gastrointestinal Disorders: abdominal pain, gastritis, dyspepsia, vomiting General Disorders and Administration Site Conditions: asthenia Hepatobiliary Disorders: hepatitis Immune System Disorders: hypersensitivity Infections and Infestations: genital herpes, herpes zoster Nervous System Disorders: dizziness Psychiatric Disorders: depression (particularly in subjects with a pre-existing history of psychiatric illness), including suicidal ideation and behaviors Renal and Urinary Disorders: nephrolithiasis, renal failure 6.3 Selected Adverse Events Cancers were reported in treatment-experienced subjects who initiated ISENTRESS or placebo, both with OBT, and in treatment-naïve subjects who initiated ISENTRESS or efavirenz, both with emtricitabine (+) tenofovir; several were recurrent. The types and rates of specific cancers were those expected in a highly immunodeficient population (many had CD4+ counts below 50 cells/mm 3 and most had prior AIDS diagnoses). The risk of developing cancer in these studies was similar in the group receiving ISENTRESS and the group receiving the comparator. Grade 2-4 creatine kinase laboratory abnormalities were observed in subjects treated with ISENTRESS (see Table 6 ). Myopathy and rhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions. Rash occurred more commonly in treatment-experienced subjects receiving regimens containing ISENTRESS + darunavir/ritonavir compared to subjects receiving ISENTRESS without darunavir/ritonavir or darunavir/ritonavir without ISENTRESS. However, rash that was considered drug related occurred at similar rates for all three groups. These rashes were mild to moderate in severity and did not limit therapy; there were no discontinuations due to rash. 6.4 Patients with Co-existing Conditions Patients Co-infected with Hepatitis B and/or Hepatitis C Virus In the randomized, double-blind, placebo-controlled trials, treatment-experienced subjects (N = 114/699 or 16%) and treatment-naïve subjects (N = 34/563 or 6%) with chronic (but not acute) active hepatitis B and/or hepatitis C virus co-infection were permitted to enroll provided that baseline liver function tests did not exceed 5 times the upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with hepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without hepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-infection for all treatment groups. In treatment-experienced subjects, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 29%, 34% and 13%, respectively, of co-infected subjects treated with ISENTRESS as compared to 11%, 10% and 9% of all other subjects treated with ISENTRESS. In treatment-naïve subjects, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 17%, 33% and 17%, respectively, of co-infected subjects treated with ISENTRESS as compared to 8%, 10% and 5% of all other subjects treated with ISENTRESS. 6.5 Clinical Trials Experience: Pediatrics ISENTRESS has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 through 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 [see Use in Specific Populations (8.4) and Clinical Studies (14.3) ] . Of the 126 patients, 96 received the recommended dose of ISENTRESS. In these 96 children and adolescents, frequency, type and severity of drug related adverse reactions through Week 24 were comparable to those observed in adults. One patient experienced drug related clinical adverse reactions of Grade 3 psychomotor hyperactivity, abnormal behavior and insomnia; one patient experienced a Grade 2 serious drug related allergic rash. One patient experienced drug related laboratory abnormalities, Grade 4 AST and Grade 3 ALT, which were considered serious. 6.6 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ISENTRESS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: thrombocytopenia Gastrointestinal Disorders: diarrhea Hepatobiliary Disorders: hepatic failure (with and without associated hypersensitivity) in patients with underlying liver disease and/or concomitant medications Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis Nervous System Disorders: cerebellar ataxia Psychiatric Disorders: anxiety, paranoia

<table ID="table2" width="75%"> <caption>Table 2: Adverse Drug Reactions<footnote ID="table2a">Includes adverse experiences considered by investigators to be at least possibly, probably, or definitely related to the drug.</footnote> of Moderate to Severe Intensity<footnote ID="table2b">Intensities are defined as follows: Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating with inability to work or do usual activity).</footnote> Occurring in &#x2265;2% of Treatment-Na&#xEF;ve Adult Subjects Receiving ISENTRESS (156 Week Analysis)</caption> <col width="33%" align="left" valign="top"/> <col width="34%" align="center" valign="top"/> <col width="33%" align="center" valign="top"/> <thead> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" rowspan="2" align="center">System Organ Class, Preferred Term</th> <th styleCode="Rrule" colspan="2">Randomized Study Protocol 021</th> </tr> <tr styleCode="Botrule"> <th styleCode="Rrule" align="center">ISENTRESS 400 mg Twice Daily + Emtricitabine (+) Tenofovir (n = 281)<footnote ID="table2c">n = total number of subjects per treatment group </footnote> </th> <th styleCode="Rrule">Efavirenz 600 mg At Bedtime + Emtricitabine (+) Tenofovir (n = 282)<footnoteRef IDREF="table2c"/> </th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Psychiatric Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Insomnia</td> <td styleCode="Rrule">4%</td> <td styleCode="Rrule">4%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Nervous System Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Headache</td> <td styleCode="Rrule">4%</td> <td styleCode="Rrule">5%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Gastrointestinal Disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nausea</td> <td styleCode="Rrule">3%</td> <td styleCode="Rrule">4%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">General Disorders and Administration</content> </td> </tr> <tr> <td styleCode="Lrule Rrule">Fatigue</td> <td styleCode="Rrule">2%</td> <td styleCode="Rrule">3%</td> </tr> </tbody> </table>

<table ID="table3" width="75%"> <caption>Table 3: Selected Grade 2 to 4 Laboratory Abnormalities Reported in Treatment-Na&#xEF;ve Subjects (156 Week Analysis)</caption> <col width="25%" align="left" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <thead> <tr> <th styleCode="Lrule "/> <th/> <th styleCode="Rrule" colspan="2">Randomized Study Protocol 021</th> </tr> <tr> <th styleCode="Lrule " align="center">Laboratory Parameter Preferred Term (Unit)</th> <th>Limit</th> <th>ISENTRESS 400 mg Twice Daily + Emtricitabine (+) Tenofovir (N = 281)</th> <th styleCode="Rrule">Efavirenz 600 mg At Bedtime + Emtricitabine (+) Tenofovir (N = 282)</th> </tr> </thead> <tfoot> <tr> <td colspan="4" align="left">ULN = Upper limit of normal range</td> </tr> </tfoot> <tbody> <tr> <td styleCode="Lrule Botrule Rrule" colspan="4"> <content styleCode="bold">Hematology </content> </td> </tr> <tr> <td styleCode="Lrule" colspan="3">Absolute neutrophil count (10³/&#xB5;L)</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>0.75 - 0.999</td> <td>3%</td> <td styleCode="Rrule">5%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>0.50 - 0.749</td> <td>2%</td> <td styleCode="Rrule">1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&lt;0.50</td> <td>&lt;1%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr> <td styleCode="Lrule" colspan="3">Hemoglobin (gm/dL)</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>7.5 - 8.4</td> <td>1%</td> <td styleCode="Rrule">1%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>6.5 - 7.4</td> <td>&lt;1%</td> <td styleCode="Rrule">1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&lt;6.5</td> <td>&lt;1%</td> <td styleCode="Rrule">0%</td> </tr> <tr> <td styleCode="Lrule" colspan="3">Platelet count (10³/&#xB5;L)</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>50 - 99.999</td> <td>2%</td> <td styleCode="Rrule">0%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>25 - 49.999</td> <td>&lt;1%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&lt;25</td> <td>0%</td> <td styleCode="Rrule">0%</td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" colspan="4"> <content styleCode="bold">Blood chemistry</content> </td> </tr> <tr> <td styleCode="Lrule" colspan="3">Fasting (non-random) serum glucose test (mg/dL)</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>126 - 250</td> <td>4%</td> <td styleCode="Rrule">5%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>251 - 500</td> <td>1%</td> <td styleCode="Rrule">1%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&gt;500</td> <td>0%</td> <td styleCode="Rrule">0%</td> </tr> <tr> <td styleCode="Lrule" colspan="3">Total serum bilirubin</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>1.6 - 2.5 &#xD7; ULN</td> <td>5%</td> <td styleCode="Rrule">0%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>2.6 - 5.0 &#xD7; ULN</td> <td>1%</td> <td styleCode="Rrule">0%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&gt;5.0 &#xD7; ULN</td> <td>&lt;1%</td> <td styleCode="Rrule">0%</td> </tr> <tr> <td styleCode="Lrule" colspan="3">Serum aspartate aminotransferase</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>2.6 - 5.0 &#xD7; ULN</td> <td>5%</td> <td styleCode="Rrule">7%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>5.1 - 10.0 &#xD7; ULN</td> <td>3%</td> <td styleCode="Rrule">3%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&gt;10.0 &#xD7; ULN</td> <td>1%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr> <td styleCode="Lrule" colspan="3">Serum alanine aminotransferase</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>2.6 - 5.0 &#xD7; ULN</td> <td>10%</td> <td styleCode="Rrule">9%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>5.1 - 10.0 &#xD7; ULN</td> <td>1%</td> <td styleCode="Rrule">2%</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> Grade 4</td> <td>&gt;10.0 &#xD7; ULN</td> <td>1%</td> <td styleCode="Rrule">1%</td> </tr> <tr> <td styleCode="Lrule" colspan="3">Serum alkaline phosphatase</td> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule"> Grade 2</td> <td>2.6 - 5.0 &#xD7; ULN</td> <td>1%</td> <td styleCode="Rrule">3%</td> </tr> <tr> <td styleCode="Lrule"> Grade 3</td> <td>5.1 - 10.0 &#xD7; ULN</td> <td>0%</td> <td styleCode="Rrule">&lt;1%</td> </tr> <tr> <td styleCode="Lrule"> Grade 4</td> <td>&gt;10.0 &#xD7; ULN</td> <td>0%</td> <td styleCode="Rrule">&lt;1%</td> </tr> </tbody> </table>

<table ID="table4" width="100%"> <caption>Table 4: Lipid Values, Mean Change from Baseline, Protocol 021</caption> <col width="18%" align="left" valign="top"/> <col width="10%" align="center" valign="top"/> <col width="10%" align="center" valign="top"/> <col width="21%" align="center" valign="top"/> <col width="10%" align="center" valign="top"/> <col width="10%" align="center" valign="top"/> <col width="21%" align="center" valign="top"/> <thead> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" align="center">Laboratory Parameter Preferred Term </th> <th styleCode="Rrule" colspan="3">ISENTRESS 400 mg Twice Daily + Emtricitabine (+) Tenofovir N = 281</th> <th styleCode="Rrule" colspan="3">Efavirenz 600 mg At Bedtime + Emtricitabine (+) Tenofovir N = 282</th> </tr> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" rowspan="2"/> <th styleCode="Rrule" colspan="2"/> <th styleCode="Rrule">Change from Baseline at Week 144</th> <th styleCode="Rrule" colspan="2"/> <th styleCode="Rrule">Change from Baseline at Week 144</th> </tr> <tr> <th styleCode="Rrule" align="center">Baseline Mean (mg/dL)</th> <th styleCode="Rrule">Week 144 Mean (mg/dL)</th> <th styleCode="Rrule">Mean Change (mg/dL)</th> <th styleCode="Rrule">Baseline Mean (mg/dL)</th> <th styleCode="Rrule">Week 144 Mean (mg/dL)</th> <th styleCode="Rrule">Mean Change (mg/dL)</th> </tr> </thead> <tfoot> <tr> <td colspan="7" align="left">Notes:</td> </tr> <tr> <td colspan="7" align="left">N = Number of subjects in the treatment group. The analysis is based on all available data.</td> </tr> <tr> <td colspan="7" align="left">If subjects initiated or increased serum lipid-reducing agents, the last available lipid values prior to the change in therapy were used in the analysis. If the missing data was due to other reasons, subjects were censored thereafter for the analysis. At baseline, serum lipid-reducing agents were used in 5% of subjects in the group receiving ISENTRESS and 3% in the efavirenz group. Through Week 144, serum lipid-reducing agents were used in 9% of subjects in the group receiving ISENTRESS and 10% in the efavirenz group.</td> </tr> </tfoot> <tbody> <tr> <td styleCode="Lrule Rrule">LDL-Cholesterol<footnote ID="table4a">Fasting (non-random) laboratory tests at Week 144.</footnote> </td> <td styleCode="Rrule">97</td> <td styleCode="Rrule">105</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">92</td> <td styleCode="Rrule">115</td> <td styleCode="Rrule">22</td> </tr> <tr> <td styleCode="Lrule Rrule">HDL-Cholesterol<footnoteRef IDREF="table4a"/> </td> <td styleCode="Rrule">38</td> <td styleCode="Rrule">43</td> <td styleCode="Rrule">4</td> <td styleCode="Rrule">38</td> <td styleCode="Rrule">48</td> <td styleCode="Rrule">11</td> </tr> <tr> <td styleCode="Lrule Rrule">Total Cholesterol<footnoteRef IDREF="table4a"/> </td> <td styleCode="Rrule">160</td> <td styleCode="Rrule">172</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">156</td> <td styleCode="Rrule">195</td> <td styleCode="Rrule">39</td> </tr> <tr> <td styleCode="Lrule Rrule">Triglyceride<footnoteRef IDREF="table4a"/> </td> <td styleCode="Rrule">126</td> <td styleCode="Rrule">127</td> <td styleCode="Rrule">1</td> <td styleCode="Rrule">139</td> <td styleCode="Rrule">173</td> <td styleCode="Rrule">35</td> </tr> </tbody> </table>